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Abstract
Spontaneous CD4
+ T-cell responses to the tumor-specific antigen NY-ESO-1 (ESO) are frequently found in patients with
epithelial ovarian cancer (EOC). If these responses are of effector or/and Treg type, however, has remained unclear. Here, we
have used functional approaches together with recently developed MHC class II/ESO tetramers to assess the frequency,
phenotype and function of ESO-specific cells in circulating lymphocytes from EOC patients. We found that circulating ESO-
specific CD4
+ T cells in EOC patients with spontaneous immune responses to the antigen are prevalently TH1 type cells
secreting IFN-c but no IL-17 or IL-10 and are not suppressive. We detected tetramer
+ cells ex vivo, at an average frequency of
1:25000 memory cells, that is, significantly lower than in patients immunized with an ESO vaccine. ESO tetramer
+ cells were
mostly effector memory cells at advanced stages of differentiation and were not detected in circulating CD25
+FOXP3
+Treg.
Thus, spontaneous CD4
+ T-cell responses to ESO in cancer patients are prevalently of TH1 type and not Treg. Their relatively
low frequency and advanced differentiation stage, however, may limit their efficacy, that may be boosted by immunogenic
ESO vaccines.
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Introduction
CD4
+ T-cell subsets play important and potentially opposite
roles in tumor immunosurveillance [1,2]. Type I helper (TH1) T
cells, secreting the signature cytokine IFN-c, favor the develop-
ment of CD8
+ cytolytic effectors (CTL), and mediate efficient anti-
tumor responses. In contrast, regulatory/suppressor T cells (Treg),
characterized ex vivo by high expression of the IL-2R a-chain
(CD25) and of the lineage-specific transcription factor FOXP3 and
low expression of the IL-7R a-chain (CD127), are believed to
inhibit anti-tumor responses [3,4,5,6,7]. Treg, that fail to secrete
IFN-c or IL-2, have been reported to be present in increased
proportions in cancer patients as compared to healthy individuals
[8,9]. Because the antigen specificity of Treg is largely unknown, it
is unclear if the ability of Treg to inhibit anti-tumor responses is
related or not to the presence/prevalence among them of tumor-
antigen specific CD4
+ T cells.
NY-ESO-1 (ESO), a tumor-specific antigen of the cancer/
testis group frequently expressed in human tumors of different
histological types, including ovarian cancers, but not in normal
somatic tissues [10,11], is a candidate for the development of
generic anticancer vaccines [12]. ESO is highly immunogenic and
elicits spontaneous humoral, CD4
+ and CD8
+ T-cell responses
in patients bearing antigen-expressing tumors [11,13,14,15]. In
addition, ESO-specific antibody, CD4
+ and CD8
+ T-cell respons-
es can be induced through immunization with ESO-based
vaccines [16]. We have previously identified immunodominant
regions recognized by ESO-specific CD4
+ and CD8
+ T cells [16]
and have generated soluble fluorescent MHC class I and, recently,
MHC class II/ESO peptide tetramers allowing the direct
detection, phenotyping and isolation of ESO-specific T cells
[17,18]. Using MHC class II/ESO peptide tetramers to assess
specific CD4
+ T cells in patients immunized with a recombinant
ESO protein administered with Montanide
TM ISA 51 and GpG
7909, we have shown that vaccine-induced ESO-specific CD4
+ T
cells are prevalently TH1 cells, are detected ex vivo among memory
(CD45RA
2) cells, include both central memory (CCR7
+) and
effector memory (CCR7
2) populations and do not include sig-
nificant proportions of Treg [16,17,18]. Recent studies, however,
have suggested that, in contrast to ESO-specific CD4
+ T cells
primed through vaccination, ESO-specific CD4
+ T cells in pa-
tients with spontaneous immune responses may contain significant
proportions of Treg [19] and that elevated proportions of cir-
culating Treg in cancer patients may impair their responsiveness
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22845to ESO vaccines [20]. To address these concerns, in this study, we
have used functional approaches, together with MHC class II/
ESO peptide tetramers to assess ESO-specific cells among con-
ventional and Treg CD4
+ T-cell subsets in circulating lymphocytes
of epithelial ovarian cancer (EOC) patients with detectable
spontaneous immune responses to ESO.
Results
Assessment of memory conventional CD25
2 and
regulatory CD25
+FOXP3
+ CD4
+ T-cell subsets in circulating
lymphocytes of healthy donors and EOC patients
Among memory CD4
+ T cells several subsets can be dis-
tinguished based on the expression of CD25 and CD127. Whereas
conventional CD4
+ T cells are CD25
2CD127
+, Treg are
CD25
+CD127
2 and FOXP3
+ (Figure 1A). A third population,
CD25
2CD127
2, contains recently activated and IL-10-producing
CD4
+ T cells [21]. Whereas CD25
2CD127
+ cells are the majority
of circulating memory CD4
+ T cells, Treg and CD25
2CD127
2
populations are present in much lower and roughly equivalent
proportions, representing each about 5%. Because previous
reports have indicated that Treg populations can be increased in
circulating lymphocytes from cancer patients as compared to
healthy individuals, we compared the proportion of CD4
+ T-cell
subsets in circulating lymphocytes of EOC patients to healthy
donors. We failed, however, to detect any significant differences
in the proportion of circulating Treg in patients as compared
to healthy donors (Figure 1B). Similarly, the proportion of
CD25
2CD127
2 CD4
+ T cells did not significantly differ between
patients and healthy donors. To further characterize CD4
+ T-cell
subsets in circulating lymphocytes from EOC patients, we isolated
them ex vivo, by flow cytometry cell sorting, stimulated them in vitro
and assessed the cultures 12 days later for their capacity to secrete
different cytokines. As expected, in both healthy donors and
patients, CD25
2 populations contained significantly higher pro-
portions of cells secreting IFN-c as compared to Treg (Figure 2).
CD127
+ populations contained higher proportions of IFN-
c-secreting cells than CD127
2 populations. Interestingly, as com-
pared to healthy donors, CD25
2CD127
2 populations from cancer
patients contained higher proportions of IFN-c-secreting cells. In
contrast, the proportion of IL-17- or IL-10-secreting cells was not
significantly different between healthy donors and patients for any
of the populations.
ESO-specific circulating CD4
+ T cells from EOC patients
with spontaneous immune responses are found in
CD25
2CD127
+ and CD25
2CD127
2 populations but not
in CD25
+CD127
2FOXP3
+Treg and secrete IFN-c but not
IL-17 or IL-10
According to previous studies, about 40% of ovarian tumors
express ESO and about 30% of EOC patients bearing ESO-
expressing tumors develop specific spontaneous antibody (Ab)
responses [22]. We assessed Ab responses to ESO in a cohort of
110 EOC patients (Table 1) in the patients’ sera by ELISA as
described [14]. We detected significant Ab responses to ESO in 8
(7%) of the patients (Figure 3A) at titers varying between 1:500 and
1:50000 (Figure 3B). Patients with detectable ESO Ab presented
with high grade (II, III) tumors at stage III or IV and with serous
histology (Table 1). For 6 patients, PBMC were available for
analysis. To assess ESO-specific cells within defined circulating
memory CD4
+ T-cell subsets of these patients, we isolated them ex
vivo by flow cytometry cell sorting, and stimulated them with a pool
of long overlapping peptides spanning the ESO sequence, as
described [16]. Twelve days later, we stimulated aliquots of the
cultures with the ESO peptide pool and assessed specific cytokine
production by intracellular staining. We detected significant
proportions of cells producing IFN-c in response to ESO in
cultures from circulating CD25
2CD127
+ and CD25
2CD127
2
CD4
+ T-cell populations, but not from Treg (Figure 4A and 4B).
In contrast, we found only low proportions of cells secreting IL-10
or IL-17 in response to ESO in any of the populations. Together,
these results indicated that the large majority of circulating ESO-
specific CD4
+ T cells in these patients were TH1 type IFN-c-
secreting cells, CD25
2, both CD127
+ and CD127
2, and were not
detectable in CD25
+FOXP3
+Treg.
Assessment of ESO-specific T cells in CD4
+ subsets using
MHC class II/ESO peptide tetramers
One caveat of the experimental setting used above was that,
whereas ESO-specific cells were detected based on their capacity
to specifically secrete IFN-c in response to ESO, Treg secreted
little IFN-c even upon stimulation with PMA/ionomycin
(Figure 2). To overcome the limitations imposed by the detection
of ESO-specific CD4
+ T cells based on functional assays, we have
recently developed soluble fluorescent MHC class II tetramers that
incorporate an immunodominant epitope from ESO, correspond-
ing to peptide 119–143 [17,18]. We have shown that MHC class
Figure 1. Phenotypic assessment of memory conventional and
regulatory CD4
+ T-cell subsets in circulating lymphocytes of
healthy donors and EOC patients. A. CD4
+ T cells were stained with
anti-FOXP3, -CD25, -CD45RA and CD127 antibodies and analyzed by
flow cytometry. Expression of CD25 and CD127 defines 3 populations of
memory (CD45RA
2) CD4
+ T cells: conventional CD25
2CD127
+ and
CD25
2CD127
2 and Treg CD25
+CD127
2 (left dot plot, numbers
correspond to the proportion of each subset among memory CD4
+ T
cells). Histograms show the expression of FOXP3 in the defined memory
CD4
+ T-cell subsets. B. The proportion of conventional CD25
2CD127
+
and CD25
2CD127
2 and Treg CD25
+CD127
2 subsets, defined in A,
among memory CD4
+ T cells of healthy donors (HD, n=27) and patients
(P, n=18).
doi:10.1371/journal.pone.0022845.g001
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+ T cells in
circulating lymphocytes of patients immunized with an ESO
recombinant vaccine with high efficiency and specificity, allowing
their direct visualization among polyspecific CD4
+ T-cell cultures.
Because 4 patients with spontaneous immune responses to ESO
expressed MHC class II alleles for which the suitable tetramers
were available (DR52b and DR4), we assessed ESO-specific T
cells in these cultures by tetramer staining (Figure 4C and 4D). We
detected significant proportions of ESO tetramer
+ cells in cultures
from CD25
2CD127
+ populations from all patients as well as in
those from the CD25
2CD127
2 populations (in 3 patients at sig-
nificantly increased frequency as compared to the CD25
2CD127
+
fractions). However, in all cases, we failed to detect significant
proportions of tetramers
+ cells in Treg cultures. In addition to
CD25
+CD127
2FOXP3
+Treg, suppressive CD4
+ T cells have also
been described in some studies among other populations [21]. To
assess if, regardless of their phenotype, ESO-specific CD4
+ T cells
displayed suppressive functions, we isolated them from the cultures
by tetramer- or IFN-c-guided cell sorting and assessed them
functionally in a suppression assay as described [23,24]. As
expected, FOXP3
+Treg populations simultaneously assessed as
internal controls efficiently suppressed the growth of responder
cells. In contrast, ESO-specific cells isolated from both CD25
2-
CD127
+ and CD25
2CD127
+ cultures were FOXP3
2 and were
not suppressive (Figure 5).
Ex vivo assessment of ESO-specific circulating CD4
+ T
cells using MHC class II/ESO tetramers
To confirm the distribution of ESO-specific cells in CD4
+ T-cell
subsets in patients with spontaneous immune responses and
further assess their proportions and phenotype, we stained total
circulating CD4
+ T cells from DR52b
+ patients ex vivo with ESO
tetramers in combination with mAb directed against markers that
characterize distinct differentiation stages of CD4
+ T cells. As
shown previously [17], ESO tetramer
+ cells were not detectable in
CD4
+ T cells from healthy donors. In contrast, they were clearly
Figure 2. Functional assessment of memory conventional and regulatory CD4
+ T-cell subsets in circulating lymphocytes of healthy
donors and EOC patients. Ex vivo-sorted memory conventional, CD25
2CD127
+ and CD25
2CD127
2, and Treg, CD25
+CD127
2, populations from
healthy donors (HD, n=12) and patients (P, n=12) were stimulated in vitro and day 12 cultures were assessed for IFN-c, IL-10 and IL-17 production,
following stimulation with PMA and ionomycin, in a 4-h intracellular cytokine secretion assay and analyzed by flow cytometry. Dot plots for one
donor are shown in A and data for all healthy donors and patients are summarized in B. Statistical analyses were performed using a standard two-
tailed t-test.
doi:10.1371/journal.pone.0022845.g002
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+ T cells from the
patients (Figure 6A). Tetramer
+ cells in circulating CD4
+ T cells
from the patients were uniformly CD25
2 and were found among
both CD127
+ and CD127
2 populations, but were not detectable
among CD25
+CD127
2 Treg (Figure 6B). Thus, similar to what
we have previously observed in patients immunized with a
recombinant ESO vaccine, direct ex vivo staining with ESO
tetramers confirmed the lack of significant proportions of ESO-
specific CD4
+ T cells in circulating Treg of patients with
spontaneous immunological responses to the antigen. The
frequency of circulating ESO tetramers
+ cells in the patients with
spontaneous responses, was, in average, of 1:25000, five folds
lower than that found in vaccinated patients (Figure 6A) [17].
However, ESO tetramer
+ cells in patients with spontaneous
responses contained lower proportions of CD127
2 cells as com-
pared to those of vaccinated patients (Figure 6B). In addition, in
contrast to the latter, which contained, in average, roughly
comparable proportions of CCR7
+ and CCR7
2 cells, as well as a
large majority of CD27
+ cells, ESO tetramer
+ cells in patients
with spontaneous responses were mostly CCR7
2 and contained
increased proportions of CD27
2 cells, consistent with a more
differentiated phenotype (Figure 6C). Finally, to exclude the
possibility that the selection of ESO Ab
+ patients may have
selected for patients with low or absent ESO-specific Treg, we
assessed ex vivo CD4
+ T cells from ESO Ab
2 DR52b
+ patients
(n=23). However, we failed to detect significant levels of ESO
tetramer
+ in these patients (data not shown).
Discussion
Strong immune responses to cancerous tissues are potentially
able to prevent disease progression. Because these responses, often
directed not exclusively against tumor-specific antigens, but also
against differentiation or other self-antigens, have the potential to
considerably damage normal tissues, robust immunoregulatory
networks are in place [25]. In particular, CD4
+CD25
+FOXP3
+-
Treg, involved in maintaining tissue homeostasis and self-
tolerance, are believed to play a major role in dampening
anticancer immunity. Previous studies have reported increased
proportions of Treg in the circulation of at least part of patients
with solid tumors [8,9] as well as accumulation of CD25
+-
FOXP3
+Treg at tumor sites [8,26], particularly at advanced stages
of disease, and have established a correlation between their
frequency and clinical outcomes [3]. On the base of these findings,
approaches for eliminating Treg have been designed, and are
already being assessed in clinical settings, although they are linked
with the risk of unleashing auto-reactivity [27,28,29].
In this study, we have addressed the presence and distribution of
CD4
+ T cells specific for the tumor antigen ESO, of the cancer/
testis group [10,30,31], within circulating CD4
+ T-cell subsets of
EOC patients. We used a combination of functional approaches
and MHC class II tetramers incorporating an immunodominant
peptide, ESO119–143, that we have recently developed [17,18]. We
found no significant differences in the proportion of Treg among
circulating lymphocytes of EOC patients as compared with
healthy donors. Similarly, we found no significant increase in
the proportion of total circulating CD4
+ CD25
2CD127
2 T cells,
a population that contains recently activated CD4
+ T cells and has
been proposed to contain IL-10-secreting Tr1 cells in healthy
donors [21] but had not been assessed in cancer patients prior to
this study. Thus, whereas alterations in the circulating Treg
compartment may indeed occur in some cancer patients, we found
no major alterations in our group of EOC patients. It is note-
worthy, however, that the patients assessed in the present study
had received first line chemotherapy, which may temporarily
reduce Treg [32], although they were assessed at various times,
but at least one month, after termination of treatment. However,
assessment of the immune status of this population, with respect to
anti-tumor responses, is most relevant for the design of immune-
based treatments.
Figure 3. Assessment of ESO-specific antibody responses in
sera of EOC patients. A. The presence of ESO-specific Ab in patients’
sera was assessed by ELISA. Sera were initially assessed at a 1:100
dilution on rESO-coated or on control uncoated plates. Sera were
scored as ESO Ab
+ if the optical density (OD) values obtained on rESO-
coated plates were both at least 3 folds higher than those obtained for
the same sample on uncoated plates and higher than the mean+6xSD
of OD values obtained with sera from healthy individuals on rESO-
coated plates (n=53, mean+6xSD =750, data not shown). B. Serial
dilutions of ESO Ab
+ sera were tested on rESO-coated plates. Serum
titer was calculated as the serum dilution yielding 50% of maximal OD.
doi:10.1371/journal.pone.0022845.g003
Table 1. Patient characteristics.
Total cohort ESO Ab
+
110 8 (7%)
Age
* [mean (range)], years 56 (31–76) 56 (46–67)
FIGO stage, n (%)
I 29 (26)
II 11 (10)
III 59 (54) 6 (75)
IV 10 (9) 2 (25)
Undetermined 1 (1)
Histology, n (%)
Serous 63 (57) 7 (88)
Clear cell 11 (10)
Endometriod 15 (14)
Mucinous 4 (4)
Undifferientiated 8 (7) 1 (12)
Others (mixed, carcinosarcoma) 7 (6)
Undetermined 2 (2)
Grade, n (%)
1 15 (14)
2 31 (28) 5 (63)
3 47 (43) 2 (25)
Undetermined 17 (15) 1 (12)
*Age at diagnosis.
doi:10.1371/journal.pone.0022845.t001
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+ T-cell
subsets from EOC patients with spontaneous immune responses,
sorted ex vivo and stimulated in vitro with ESO peptides, we detected
significant proportions of cells producing IFN-c in response to
ESO, but no IL-10- or IL-17-secreting cells, indicating that the
majority of ESO-specific CD4
+ T cells were TH1 effectors.
Because this study specifically addressed TH1 cells and Treg in
EOC, we limited the analysis to the most relevant cytokines,
namely IFN-c, IL-10 and, because of the reported relationship
between Treg and TH17 cells, IL-17. It will however be of interest,
in future studies, to address the production of additional cytokines
such as IL-4 or IL-13, by ESO specific CD4
+ T cells. In line with
the conclusion that ESO-specific CD4
+ T cells isolated from the
cultures are effector cells, they did not exhibit significant sup-
pressive functions. In addition, we did not detect ESO-specific cells
in circulating Treg of patients with spontaneous immune responses
to the antigen by staining, with MHC class II/ESO tetramers, of
defined conventional and Treg CD4
+ T-cell subpopulations
isolated ex vivo by flow cytometry cell sorting, as well as by direct
ex vivo staining with tetramers. At variance with our data, previous
studies have reported the isolation of ESO-specific CD4
+ T cells
with suppressive functions from circulating lymphocytes of patients
with advanced melanoma [19,33]. Thus, whereas our data do not
exclude the existence of ESO-specific Treg, they imply that the
latter are not commonly found in circulating CD4
+ T cells from
EOC patients. It is also noteworthy that, consistent with our
Figure 4. Assessment of ESO-specific cells in circulating memory CD4
+ T-cell subsets of EOC patients. Memory conventional,
CD25
2CD127
+ and CD25
2CD127
2, and Treg, CD25
+CD127
2, populations were sorted ex vivo from CD4
+ T cells of ESO Ab
+ patients and stimulated in
vitro with a pool of long overlapping peptides spanning the full length ESO sequence. A and B. Day 12 cultures were assessed for IFN-c, IL-10 and IL-
17 production in a 4-h intracellular cytokine staining assay following stimulation in the absence or presence of the ESO peptide pool. Dot plots for
one patient are shown in A and data obtained for all patients are summarized in B. C and D. Day 12 cultures were stained with DR52b/ESO119–143
(NA017, NA093 and NA097) or DR4/ESO119–143 (NA304) tetramers and anti-CD4 mAb and analyzed by flow cytometry. Dot plots for one patient are
shown in C and data for all patients are summarized in D.
doi:10.1371/journal.pone.0022845.g004
NY-ESO-1-Specific CD4 T Cells in Ovarian Cancer
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22845results, studies in mouse models have examined the presence of
Treg in antigen-specific T cells with tetramers and failed to detect
tetramer-binding Treg [34,35].
Using MHC class II/ESO119-143 tetramers ex vivo, we could
directly compare ESO-specific CD4
+ T cells spontaneously arising
in patients, with those induced through vaccination with a
recombinant ESO protein (rESO) administered with Montani-
de
TM and CpG [16]. It is noteworthy that until the recent
development of MHC class II/peptide tetramers, it has been
difficult to assess antigen-specific CD4
+ T cells ex vivo due to their
generally low frequency. This is indeed the first report character-
izing CD4
+ T cells specific for a cancer/testis antigen in cancer
patients with spontaneous immune responses ex vivo. We found that
the frequency of CD4
+ T cells specific for ESO was significantly
lower in patients with spontaneous immune responses as com-
pared to that found in vaccinated patients. In addition, the
phenotype of naturally-arising ESO tetramer
+ cells was more
differentiated, as compared to their vaccine-induced counterparts,
containing increased proportions of CCR7
2 and CD27
2 cells.
Previous studies exploring the correlation between the quality of
memory CD4
+ T-cell responses elicited by pathogens or vaccines
and their phenotype, have suggested that a protective memory
response should include not only effectors (CCR7
2) but memory
cells at earlier differentiation stages, namely central memory
(CCR7
+) and transitional memory (CCR7
2CD27
+) T cells [36,37].
Based on this concept,ourresults suggest that ESO-specificCD4
+ T
cells induced through immunization of cancer patients with the
rESO vaccine are likely to be not only quantitatively but also
qualitatively superior to those arising during spontaneous immune
responses, which further encourages the use of ESO-based vaccines
in patients bearing ESO-expressing tumors.
Together, these results underline the potential of MHC class II/
ESO tetramers for the unambiguous detection, quantification and
phenotyping of ESO-specific CD4
+ T cells, not only following
vaccination, but also for assessing the immune responses that
naturally arise in patients bearing antigen-expressing tumors. The
further application of this approach for the characterization of
CD4
+ T cells specific for ESO and other tumor antigens in the
circulation and at tumor sites of cancer patients, both along the
natural course of the disease and during therapy, will likely
contribute to significantly further our understanding of their roles
and contribution in immunity to cancer.
Materials and Methods
Patient and healthy donor samples and assessment of
ESO-specific antibody responses
Sera and peripheral blood mononuclear cells (PBMC) were
collected from EOC patients seen at CLCC Rene ´ Gauducheau
and from healthy individuals upon written informed consent and
Figure 5. Assessment of the suppressive activity of ESO-specific CD4
+ T-cell polyclonal populations. ESO-specific cells were isolated
from peptide-stimulated CD25
2CD127
+ and CD25
2CD127
2 CD4
+ T-cell cultures (Figure 4) by tetramer-guided (NA017) or IFN-c-guided (NA114) flow
cytometry cell sorting and expanded in vitro. The resulting polyclonal cultures contained .80% ESO-specific cells. A. ESO-specific polyclonal cultures
as well as polyclonal cultures from the ESO
2 fraction and control cultures of in vitro-expanded conventional memory CD4
+ T cells (M) and memory
Treg (MTreg), isolated ex vivo from healthy individuals, were stained with FOXP3-specific mAb and analyzed by flow cytometry. Numbers in dot plots
correspond to the mean fluorescence intensity (MFI) of FOXP3 staining. B. The suppressive activity of ESO-specific and control polyclonal populations
was assessed by co-culture with CFSE-labeled conventional CD4
+ T cells, at a responder:suppressor ratio of 1:1, in the presence of irradiated
monocytes and PHA. Dot plots show the CFSE-dilution profile in the absence of test population (left) and in the presence of the indicated test
populations. Numbers in histograms correspond the percentage of undivided cells. Results corresponding to the calculated% suppression are shown
for all tested populations.
doi:10.1371/journal.pone.0022845.g005
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22845Figure 6. Ex vivo assessment of ESO-specific CD4
+ T cells using DR52b/ESO tetramers. CD4
+ T cells from DR52b
+ healthy donors (HD) and
patients were stained ex vivo with DR52b/ESO119–143 tetramers and mAb specific for CD45RA, CD25, CD127, CCR7 and CD27 and analyzed by
flow cytometry. A. Dot plots for one HD and one EOC patient are shown. Numbers in dot plots correspond to the percentage of tetramer
+ cells
among CD45RA
2 memory cells. Data for all EOC patients with spontaneous immune responses to ESO (S) are shown in comparison to the
frequency (mean 6 SD) of ESO tetramer
+ cells in post-vaccine samples from patients having received a recombinant ESO vaccine (V) [17]. B.D o t
plots show the expression of CD25 and CD127 in total memory cells and in tetramer
+ cells of one EOC patient. Data corresponding to the
proportion of conventional, CD25
2CD127
+ and CD25
2CD127
2,a n dT r e g ,C D 2 5
+CD127
2, populations within tetramer
+ cells for all EOC patients
(S) are summarized and compared to the proportion (mean 6 SD) of these populations in vaccine-induced tetramer
+ cells (V). C. Dot plots show
the expression of CCR7 and CD27 in total memory cells and in tetramer
+ cells of one EOC patient. Data corresponding to the proportion of
CCR7
+, CCR7
2CD27
+ and CCR7
2CD27
2 populations within tetramer
+ cells for all EOC patients (S) are summarized and compared to the
proportion (mean 6 SD) of these populations in vaccine-induced tetramer
+ cells (V). Statistical analyses were performed using a standard two-
tailed t-test.
doi:10.1371/journal.pone.0022845.g006
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des Personnes Ouest IV – Nantes). Antibody (Ab) responses to
ESO were assessed by ELISA, as previously described [14,16],
using recombinant ESO protein (rESO) produced in E. coli.
Ex vivo phenotypic assessment of CD4
+ T-cell subsets
and flow cytometry cell sorting
CD4
+ T cells were enriched by positive selection from PBMC of
healthy individuals and EOC patients by magnetic cell sorting
(Miltenyi Biotec), stained with monoclonal antibodies (mAb)
specific for CD4 (BD Biosciences), CD8 (BD Biosciences),
CD45RA (BD Biosciences), CD25 (Beckman Coulter), CD127
(eBioscience) and FOXP3 (eBioscience), as indicated, and
analyzed by flow cytometry using an LSRII (BD Biosciences).
For ex vivo flow cytometry cell sorting, enriched CD4
+ T cells were
stained with anti-CD4, -CD8, -CD45RA, -CD25 and -CD127
mAb. After gating on CD4
+CD8
2CD45RA
2 lymphocytes, cells
were separated into memory CD25
2CD127
+, CD25
2CD127
2
and CD25
+CD127
2Treg populations to high purity (.97%) using
a FACSAria (BD Biosciences).
In vitro stimulation and functional assessment of CD4
+ T-
cell subsets
Total CD4
+ T cells or ex vivo sorted memory conventional and
Treg CD4
+ T-cell populations were stimulated in vitro with either a
pool of long overlapping peptides covering the ESO sequence [16]
or with anti-CD2/3/28-coated microbeads (Miltenyi Biotec) in the
presence of irradiated autologous APC and were cultured in the
presence of recombinant human IL-2 (Chiron). Day 12 to 14
cultures were assessed in a 4-h intracellular cytokine staining assay
using mAb specific for IFN-c (BD Biosciences), IL-10 (BD
Biosciences) and IL-17 (eBioscience), following stimulation with
either the ESO peptide pool or PMA (100 ng/mL, Sigma Aldrich)
and ionomycin (1 mg/mL, Sigma Aldrich), as indicated, and
analyzed by flow cytometry (LSRII).
MHC class II/ESO peptide tetramer staining
Fluorescent HLA-DR52b/and HLA-DR4/ESO119–143 tetra-
mers were generated as previously described [17,18]. ESO-
stimulated CD4
+ T-cell cultures were incubated with tetramers
at a final concentration of 3 mg/mL for 1 h at 37uC and then
stained with CD4-specific mAb and analyzed by flow cytometry
(LSRII). For ex vivo enumeration and phenotyping of specific cells,
total CD4
+ T cells enriched from PBMC by magnetic cell sorting
were rested overnight, incubated with tetramers (3 mg/mL) for 2 h
at 37uC and then stained with the indicated mAb and analyzed by
flow cytometry (LSRII).
Isolation of ESO-specific polyclonal populations and
assessment of suppressive function
ESO-specific T cells were isolated from peptide-stimulated
cultures by IFN-c secretion assay- (Miltenyi Biotec) or tetramer-
guided flow cytometry cell sorting and expanded by stimulation
with PHA and irradiated allogeneic PBMC in the presence of IL-
2, as previously described [16,17]. The specificity of the obtained
polyclonal cultures was assessed by tetramer staining or by
intracellular IFN-c staining following restimulation with ESO
peptides and FOXP3 expression was assessed by staining using
specific mAb. The suppressive activity of ESO-specific polyclonal
cultures was assessed by co-culture of CFSE-labeled responder
conventional CD4
+ T cells with or without test populations in the
presence of irradiated monocytes, enriched by positive selection
from PBMC by magnetic cell sorting (Miltenyi Biotec), and PHA,
as previously described [23,24]. Growth of responder cells was
assessed by flow cytometry analysis of CFSE dilution in day 4 to 6
cultures. The growth (100-% undivided cells) of the wells with
suppressor cells (experimental group) was compared with that of
the wells without suppressors (control). The percentage of sup-
pression was determined as follows: 100 – ((growth of experimental
group/growth of control) 6100).
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